The findings could help clinicians use neuropsychiatric symptoms to prepare patients and families for a type of dementia ...

Oral semaglutide (a GLP-1 pill) is not effective at slowing progression in patients with mild Alzheimer's disease, finds the ...

Research from UC Santa Cruz indicates that the P3 peptide—an alternative cleavage product of the amyloid precursor protein—may play a role in Alzheimer’s disease.

New findings suggest that targeting inflammation in Alzheimer’s may matter as much as targeting protein buildup.

More than 7 million Americans over 65 are living with the Alzheimer’s, but what if artificial intelligence could help predict the disease before memory loss begins? New research is using AI to analyze ...

Alzheimer's disease is the most common cause of dementia, and it affects over 7 million people in the United States alone.

Blood-based biomarkers, such as Roche’s pTau181 test, offer a powerful tool for identifying the right patients for Alzheimer’s disease clinical trials early. This October saw a landmark development in ...

Scientists have long searched for ways to treat Alzheimer’s disease, the most common form of dementia. Chief among these strategies has been targeting amyloid beta, a toxic protein that forms ...

Scientists reverse Alzheimer's memory loss in mice by using NAD+ to restore brain energy, defying decades of research.

(Microgen Images/Science Photo Library/Getty Images) Problems with sleep often show up much earlier than more recognizable ...

Some people with the gene did not have expected outcomes if they were heavy meat-eaters ...

HHS Secretary Robert F. Kennedy Jr. appointed Michelle Branham as chair of the federal Advisory Council on Alzheimer’s ...